An observational study in Genomic, Diabetes Mellitus and MODY, sponsored by Indonesia University. Recruiting at 1 site in Indonesia. Open to participants aged 8 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-22.
Sponsored by Indonesia University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Diabetes Mellitus with a site in Indonesia — 7 open to participants now, 9 under way, 1 of them phase 3. Diabetes Mellitus · Indonesia.
Among the 46 studies in Diabetes Mellitus with a site in Indonesia, this one is the 11th largest by planned enrollment of the 17 observational ones that give a count, is one of 3 that started in 2022, is one of 17 observational ones, and was the 32nd registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →7 of the 46 studies in Diabetes Mellitus with a site in Indonesia are open now. Recruiting first, the newest first:
Tarumanagara University · Sites in Indonesia
Ages 30+ · Healthy volunteers
Universitas Muhammadiyah Surakarta · Sites in Indonesia
Ages 18+
Andalas University · Sites in Indonesia
Ages 18+ · Healthy volunteers
Tarumanagara University · Sites in Indonesia
Ages 18+ · Healthy volunteers
Universitas Sebelas Maret · Sites in Indonesia
Ages 40–60
A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 8 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 3 · Phase 4 2
First in 2003; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 246 across 1,935 observational studies indexed under Diabetes Mellitus.
Median enrollment 84 across the 29 interventional studies, 1,584 across the 17 observational. Of the 30 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 46 have an industry lead sponsor. The 10 most frequent:
Indonesia University is the lead sponsor of 444 studies on the registry; 54 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
Indonesia University has 8 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetes Mellitus with a site in Indonesia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07229794St Elisabeth School Health ScienceEffect of Foot-ankle Exercise Using Elastic Band | 2026-11-30 |
| NCT07126041Oxford University Clinical Research Unit IndonesiaScalable Public Health Empowerment, Research, and Education Sites (SPHERES) | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 46 studies in Diabetes Mellitus with a site in Indonesia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Diabetes Mellitus (DM) has been a major contributor to health burden in Indonesia and currently its burden still continues to rise. This is a result of increasing DM prevalence in the country as well as high rates of chronic complications from DM. Findings in Indonesia show that there is a high proportion of young people with diabetes, and also a high risk of therapeutic failure and complications from DM occurring in the younger population.
Young-onset DM has a wide clinical spectrum, including autoimmune DM, polygenic DM, and monogenic DM such as Mature Onset Diabetes of the Young (MODY). Identification and proper diagnosis of young-onset DM spectrum is crucial to treatment outcomes, as certain spectrums, such as some subtypes of MODY, may benefit from cost-efficient alternatives with better outcomes.
However, proper diagnosis of young-onset DM in Indonesia is still a great challenge, as currently some examinations, including genetic testing, has not yet been feasibly done in the country. With current advances in genomics, genetic testing may prove to be fundamental in providing optimal and personalized treatment and care for DM patients.
This study is a pilot project aimed to initiate genomic research in young-onset DM patients in Indonesia. In the short term, this study aims to identify genetic variants that may be able to increase diagnostic accuracy of the young-onset DM spectrum. In the long term, this study aims to identify new genetic variants of young-onset DM. The study also aims to identify genetic variants associated with risks of chronic complications.
Type 2 diabetes mellitus (T2DM) is a progressive, degenerative chronic disease which clinically manifests as hyperglycemia due to resistance and/or insulin deficiency.(1) According to data from the International Diabetes Federation (IDF), in 2017, around 425 million people in the world have diabetes, and it is predicted that this figure would increase up to 629 million by 2045.(2) Currently, diabetes has become a major contributor to health burden and its prevalence has been steadily increasing. Indonesia places sixth among countries with the highest number of people with diabetes with around 10.3 million in 2017(2) which then increase to more than 19 million in 2021. This is aligned with an increase in diabetes mellitus (DM) prevalence in Indonesia from 5,6% in 2007 to 10,9% in 2018. (3,4) The high prevalence of DM in Indonesia causes great burden in its health sector, both directly and indirectly. Most of the burden brought by DMT2 is contributed by various possible complications as the disease progresses. (1) Chronic complications of DMT2 comprises of vascular disorders, both microangiopathy or macroangiopathy, metabolic disorders and increased risk of infection. (5) Microangiopathy complications include retinopathy which may lead to blindness, nephropathy which may lead to kidney failure, peripheral neuropathy which may severely affect quality of life and diabetic cardiopathy which may lead to heart failure. Macroangiopathy complications include coronary heart disease, stroke, and peripheral artery disease (PAD) which may lead to amputation. (5) Other complications include increased risk of liver cirrhosis due to fatty liver, sexual dysfunction, and increased risk of certain infections such as tuberculosis (TB). (6-8) DM is also associated with higher risk of mortality from COVID-19.
Several studies show that the rate of complications from DM is quite high. According to a study from Dr. Cipto Mangunkusumo National General Hospital in 2011, neuropathy is found to be the most frequent complication (54%), followed by retinopathy (33.4%) and proteinuria (26.5%). (9,10) Two major factors which contribute to these frequent rates of complications are late diagnosis and poor glycemic control. Another finding which may also contribute to this phenomenon is that there is a high proportion of young people with diabetes in Indonesia, whereby studies show that DM in young people has higher risks of therapeutic failure and chronic complications. (11, 12) The high rates of therapeutic failure and chronic complications in people with young-onset DM may greatly affect not only directly through financial burden from healthcare, but also indirectly through arising problems in daily life such as decreased productivity. Diabetics with chronic complication may spend more time in healthcare facilities rather than in other activities, compromising work productivity. Hence, a sufficient understanding of risk factors and clinical spectrums of young-onset DM is important for providing optimal care.
Ethnicity and intrauterine environment might be strong predictors of young-onset T2DM. (11) Obesity, history of low birth weight, and genetic factors also contribute significant roles. (11) The clinical spectrum of young-onset DM varies, including autoimmune DM, polygenic DM, and monogenic DM such as Mature Onset Diabetes of the Young (MODY). Accurate diagnosis plays an important role in providing proper treatment to prevent chronic complications.
MODY is a monogenic form of diabetes in the form of autosomal dominant non-insulin dependent diabetes. (13) MODY contributes to 1-5% of DM cases and symptoms generally appear at a young age (\<25 years old). MODY is commonly misdiagnosed as type 1 DM (T1DM) or T2DM. Molecular diagnosis is needed for the accurate diagnosis and optimal treatment of MODY. It also provides possible means to screen and provide early diagnosis of asymptomatic family members. (13) Some subtypes of MODY (HNF1A, HNF4A, KCNJ11, dan ABCC8) may optimally be treated with sulfonylureas, which would be more cost-efficient and provide better clinical outcomes compared to insulin therapy. However, this has not been feasible in Indonesia as some examinations, especially genetic testing, may only be performed by sending samples overseas which would cost greatly. This has proved to be an obstacle to providing tailored or personalized therapy for patients. Personalised medicine involves not only giving accurate diagnosis, but also providing proper choice of therapy as well as predicting possible complications that may appear so that intervention may be done early in their course. To achieve this, genetic testing might be fundamental. In the present, genomic testing in DM is rapidly and continuously developing. This study aims to initiate genomic research in young-onset DM patients in Indonesia. In the short term, this study aims to identify genetic variants that may be able to increase diagnostic accuracy of the young-onset DM spectrum. This may also serve as a baseline for providing personalised medicine care. In the long term, this study aims to identify new genetic variants of young-onset DM.
RESEARCH OBJECTIVES The overall objective of this study is to identify and describe genetic variation of young-onset DM in Indonesia.
The specific objectives are:
To describe genetic variation in young-onset DM with diabetic complications in various systems:
Study Population and Sample The study population is early-onset DM patients. Subjects will be recruited from outpatient clinics Dr. Cipto Mangunkusumo National General Hospital metabolic and endocrine outpatient clinic and KIARA pediatric endocrine outpatient clinic from September 2022 to April 2024. The study will also recruit healthy controls who fulfill the inclusion criteria. Healthy controls will be recruited from Dr. Cipto Mangunkusumo National General Hospital employees undergoing medical checkups and the general population if target sample size has not been met. The study aims to recruit 1,000 diabetic patients and 1,000 healthy controls.
Diabetic patients Inclusion criteria
Diabetic patient fulfilling criteria from Indonesian Endocrinology Association (PERKENI) 2021 guidelines:
Healthy controls Inclusion criteria
Fulfilling criteria of normal blood glucose levels according to Indonesian Endocrinology Association (PERKENI) 2021 guidelines:
The study population is early-onset DM patients. Subjects will be recruited from outpatient clinics Dr. Cipto Mangunkusumo National General Hospital metabolic and endocrine outpatient clinic and KIARA pediatric endocrine outpatient clinic from September 2022 to April 2024. The study will also recruit healthy controls who fulfill the inclusion criteria. Healthy controls will be recruited from Dr. Cipto Mangunkusumo National General Hospital employees undergoing medical checkups and the general population if target sample size has not been met. The study aims to recruit 1,000 diabetic patients and 1,000 healthy controls.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diabetic patients
Diabetic patient fulfilling criteria from Indonesian Endocrinology Association (PERKENI) 2021 guidelines:
Exclusion Criteria:
Healthy controls Inclusion criteria
Fulfilling criteria of normal blood glucose levels according to Indonesian Endocrinology Association (PERKENI) 2021 guidelines:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diabetic patients and Healthy controls
The overall objective of this study is to identify and describe genetic variation of young-onset DM in Indonesia.
Time frame: 1 years
To describe the proportion of MODY in young-onset DM
Time frame: 1 years
To describe genetic variation of MODY in Indonesia.
Time frame: 1 years
To describe genetic variation in young-onset DM with diabetic complications in various systems:
Cardiovascular complications: coronary heart disease (CHD) and diabetic cardiomyopathy b. Peripheral vascular complications c. Neurological complications: cerebrovascular disease (CVD) and peripheral neuropathy d. Diabetic nephropathy e. Diabetic retinopathy f. Fatty liver and fatty pancreas g. Hearing impairment h. Sexual dysfunction
Time frame: 1 years
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2022 (actual). Primary completion is estimated for Dec 2024, 27 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.